secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bionano Genomics, Inc. (BNGO)
CIK:        0001411690
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0001411690-24-000004
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bionano Genomics reports Q4 revenue $10.7M (+30% YoY), announces 34-39% workforce reduction
--------------------------------------------------------------------------------

- Q4 2023 revenue $10.7M, FY 2023 revenue $36.1M, both up 30% YoY.
- GAAP gross margin Q4 23%, FY 26% (up from 21% in 2022).
- Plans to cut 110-125 employees (34-39% of workforce) and phase out testing services generating 19.4% of FY 2023 revenue.
- Restructuring expected to yield $35-40M annual operating expense savings starting H2 2024.
- No specific 2024 revenue guidance provided; cash and securities $102.3M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411690/000141169024000004/0001411690-24-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411690/000141169024000004/bngo-20240301.htm
  HTML page:      https://secwatch.observer/filing/0001411690-24-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer